

SEQ ID NO:5 alignment

&lt;!--StartFragment--&gt;RESULT 2

AED67703

ID AED67703 standard; protein; 107 AA.

XX

AC AED67703;

XX

DT 26-JAN-2006 (first entry)

XX

DE Humanized FcgammaRIIB antibody 3H7 VL protein.

XX

KW monoclonal antibody; gene therapy; antibody therapy; immunotherapy;

KW vaccine; cancer; cytostatic; breast tumor; ovary tumor; prostate tumor;

KW uterine cervix tumor; pancreas tumor; chronic lymphocytic leukemia;

KW non-hodgkin lymphoma; autoimmune disease; immunosuppressive;

KW inflammation; antiinflammatory; allergy; antiallergic; fc-gamma receptor;

KW light chain variable region; humanized antibody; chimeric antibody.

XX

OS Homo sapiens.

OS Mus sp.

OS Chimeric.

XX

PN US2005260213-A1.

XX

PD 24-NOV-2005.

XX

PF 15-APR-2005; 2005US-00108135.

XX

PR 16-APR-2004; 2004US-0562804P.

PR 21-JUN-2004; 2004US-0582044P.

PR 21-JUN-2004; 2004US-0582045P.

PR 18-FEB-2005; 2005US-0654713P.

XX

PA (KOEN/) KOENIG S.

PA (VERI/) VERI M C.

PA (TUAI/) TUAILLON N.

PA (BONV/) BONVINI E.

PA (STAV/) STAVENHAGEN J.

PA (RANK/) RANKIN C.

XX

PI Koenig S, Veri MC, Tuailon N, Bonvini E, Stavenhagen J;

PI Rankin C;

XX

DR WPI; 2005-796073/81.

DR N-PSDB; AED67702.

XX

PT New isolated antibody that specifically binds the extracellular domain of  
 PT native human Fc gamma-RIIB with greater affinity than the antibody that  
 PT binds native human Fc gamma-RIIA, useful for preventing or treating B-  
 PT cell malignancy.

XX

PS Disclosure; SEQ ID NO 46; 146pp; English.

XX

CC The invention relates to monoclonal antibodies (e.g. 2B6, 3H7) or their  
 CC fragments that specifically bind the extracellular domain of native human  
 CC FcgammaRIIB receptor with greater affinity than FcgammaRIIA antibodies or  
 CC their fragments. FcgammaRIIB antibodies are used for preventing,  
 CC treating, managing or ameliorating a cancer (e.g. breast, ovarian,  
 CC prostate, cervical or pancreatic cancer) preferably a B-cell malignancy  
 CC (e.g. B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma), an  
 CC autoimmune disorder, an inflammatory disorder and an IgE-mediated  
 CC allergic disorder. The invention is also used in vaccine therapy and gene

CC therapy. The present sequence is a humanized FcgammaRIIB antibody (3H7)  
CC light chain variable region (VL) protein. VL region consists of the  
CC framework segments from a human germline VL segment and CDR regions from  
CC mouse 3H7 VL.

XX

SQ Sequence 107 AA;

Query Match 92.3%; Score 492; DB 1; Length 107;  
Best Local Similarity 92.2%; Pred. No. 7.8e-32;  
Matches 95; Conservative 4; Mismatches 4; Indels 0; Gaps 0;

Qy 2 IQLTQSPSSLSASLGERVSLTCRASQEISGYLSWLQQKPDGTIKRLIYATSALDSGVPKR 61  
||:|||||||||||||||||||||||||||||||||||||:||||| | ||||||||

Db 2 IQMTQSPSSLSASLGERVSLTCRASQEISGYLSWLQQKPDGTIRRLIYAASTLDSGVPKR 61

Qy 62 FSGSGSGSNYSLTISSESEDFADYYCLQYANYPYTFGGGTKL 104  
|||| |||:|||||||||||||||||||:||||||||||

Db 62 FSGSWSGSDYSLTISSESEDFADYYCLQYVSYPYTFGGGTKL 104

<!--EndFragment-->